Exploiting fungal cell wall components in vaccines

Seminars in Immunopathology

Volumn 37, Issue 2, 2015, Pages 199-207

  Levitz, Stuart M ^a   Huang, Haibin ^a   Ostroff, Gary R ^a   Specht, Charles A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Chitin; Chitosan; Fungus; Mannan; Vaccine; Glucan

Indexed keywords

BETA 1,3 GLUCAN; BETA GLUCAN; CHITIN; CHITOSAN; DIPHTHERIA TOXOID LAMINARIN CONJUGATE VACCINE; FUNGUS VACCINE; GLUCURONOXYLOMANNAN TETANUS TOXOID CONJUGATE VACINE; GLYCOCONJUGATE; LAMINARAN; MANNOPROTEIN; MIMEOTOPE VACCINE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CARBOHYDRATE; FUNGUS ANTIGEN; MANNAN;

ASPERGILLOSIS; CANDIDIASIS; CELLULAR IMMUNITY; CONJUGATE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; FUNGAL CELL WALL; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; ANIMAL; CELL WALL; FUNGUS; IMMUNOLOGY; MYCOSES;

ANIMALS; ANTIGENS, FUNGAL; BETA-GLUCANS; CARBOHYDRATES; CELL WALL; CHITIN; FUNGAL VACCINES; FUNGI; HUMANS; IMMUNOCONJUGATES; MANNANS; MYCOSES;

EID: 84925541506     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-014-0460-6     Document Type: Review

References (90)

1. Levitz SM, Golenbock DT (2012) Beyond empiricism: informing vaccine development through innate immunity research. Cell 148:1284–1292
2. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33:492–503
3. McKee AS, Munks MW, Marrack P (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27:687–690
4. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287–293
5. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Sci Transl Med 4:165rv13
6. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525–530
7. Levitz SM (2010) Innate recognition of fungal cell walls. PLoS Pathog 6:e1000758
8. Rappleye CA, Eissenberg LG, Goldman WE (2007) Histoplasma capsulatum α-(1,3)-glucan blocks innate immune recognition by the beta-glucan receptor. Proc Natl Acad Sci U S A 104:1366–1370
9. Levitz SM, Tabuni A (1991) Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. J Clin Investig 87:528–535
10. Agarwal S, Specht CA, Huang H, Ostroff GR, Ram S, Rice PA, Levitz SM. 2011. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio 2
11. Novak M, Vetvicka V (2008) Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J Immunotoxicol 5:47–57
12. Weitberg AB (2008) A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. J Exp Clin Cancer Res 27:40
13. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL, Di Luzio NR (1988) Pre-clinical safety evaluation of soluble glucan. Int J Immunopharmacol 10:405–414
14. Geijtenbeek TBH, Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9:465–479
15. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis E (2007) Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 8:630–638
16. LeibundGut-Landmann S, Osorio F, Brown GD, Reis e Sousa C (2008) Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 112:4971–4980
17. Carter RW, Thompson C, Reid DM, Wong SY, Tough DF (2006) Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol 177:2276–2284
18. Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA, Levitz SM (2009) Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun 77:1774–81
19. Osorio F, Reis e Sousa C (2011) Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34:651–64
20. Huang H, Ostroff GR, Lee CK, Agarwal S, Ram S, Rice PA, Specht CA, Levitz SM (2012) Relative contributions of dectin-1 and complement to immune responses to particulate beta-glucans. J Immunol 189:312–7
21. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP (2009) Orally delivered siRNA targeting macrophage MAP4K4 suppresses systemic inflammation. Nature 458:1180–4
22. Soto ER, Ostroff GR (2008) Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug Chem 19:840–8
23. Soto ER, Caras AC, Kut LC, Castle MK, Ostroff GR (2012) Glucan particles for macrophage targeted delivery of nanoparticles. J Drug Deliv 2012:143524
24. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM (2010) Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio 1:e00164–10
25. Tesz GJ, Aouadi M, Prot M, Nicoloro SM, Boutet E, Amano SU, Goller A, Wang M, Guo CA, Salomon WE, Virbasius JV, Baum RA, O’Connor MJ Jr, Soto E, Ostroff GR, Czech MP (2011) Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J 436:351–62
26. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM (2013) Characterization and optimization of the glucan particle-based vaccine platform. Clin Vaccine Immunol: CVI 20:1585–91
27. Song Y, Luo Y, You J, Shen H, Hu S (2012) Biochemical, sensory and microbiological attributes of bream (Megalobrama amblycephala) during partial freezing and chilled storage. J Sci Food Agric 92:197–202
28. Kean T, Thanou M (2010) Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 62:3–11
29. Ardiani A, Higgins JP, Hodge JW (2010) Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Res 10:1060–9
30. Schiff ER, Everson GT, Tsai N (2007) HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: a randomized, double-blind, placebo controlled phase 1b study [abstract 1304]. Hepatol Int 46(Suppl S1):816A
31. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC, Franzusoff A (2004) Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 64:5084–8
32. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, Wilson CC (2001) Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7:625–9
33. Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, Hodge JW (2008) Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 14:4316–25
34. Gemmill TR, Trimble RB (1999) Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim Biophys Acta 1426:227–37
35. Levitz SM, Specht CA (2006) The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res 6:513–24
36. Cutler JE (2001) N-Glycosylation of yeast, with emphasis on Candida albicans. Med Mycol 39(Suppl 1):75–86
37. Ernst JF, Prill SK (2001) O-Glycosylation. Med Mycol 39(Suppl 1):67–74
38. Dan JM, Wang JP, Lee CK, Levitz SM (2008) Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS One 3:e2046
39. Geijtenbeek TB, van Vliet SJ, Engering A, 't Hart BA, van Kooyk Y (2004) Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 22:33–54
40. van Kooyk Y, Engering A, Lekkerkerker AN, Ludwig IS, Geijtenbeek TB (2004) Pathogens use carbohydrates to escape immunity induced by dendritic cells. Curr Opin Immunol 16:488–93
41. Sancho D, Reis e Sousa C (2012) Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 30:491–529
42. Hardison SE, Brown GD (2012) C-type lectin receptors orchestrate antifungal immunity. Nat Immunol 13:817–22
43. Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182:389–400
44. Engering AJ, Cella M, Fluitsma DM, Hoefsmit EC, Lanzavecchia A, Pieters J (1997) Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv Exp Med Biol 417:183–7
45. Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, Lanzavecchia A, Fransen J, Figdor CG, Piguet V, van Kooyk Y (2002) The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol 168:2118–26
46. Murphy JW, Mosley RL, Cherniak R, Reyes GH, Kozel TR, Reiss E (1988) Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun 56:424–31
47. Hoy JF, Murphy JW, Miller GG (1989) T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection. J Infect Dis 159:116–9
48. Levitz SM, North EA (1997) Lymphoproliferation and cytokines profiles in human peripheral blood mononuclear cells stimulated by Cryptococcus neoformans. J Med Vet Mycol 35:229–36
49. Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, Harrison TS, Koup RA (2013) The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis 207:1817–28
50. Chang CC, Lim A, Omarjee S, Levitz SM, Gosnell BI, Spelman T, Elliott JH, Carr WH, Moosa MY, Ndung’u T, Lewin SR, French MA (2013) Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-gamma responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 208:898–906
51. Levitz SM, Nong S, Mansour MK, Huang C, Specht CA (2001) Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc Natl Acad Sci U S A 98:10422–7
52. Huang C, Nong SH, Mansour MK, Specht CA, Levitz SM (2002) Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-cell responses. Infect Immun 70:5485–93
53. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM (2007) Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis 196:796–800
54. Lam JS, Mansour MK, Specht CA, Levitz SM (2005) A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 175:7496–503
55. Lam JS, Huang H, Levitz SM (2007) Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells. PLoS One 2:e1009
56. Luong M, Lam JS, Chen J, Levitz SM (2007) Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 25:4340–4
57. Irache JM, Salman HH, Gamazo C, Espuelas S (2008) Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 5:703–24
58. Keler T, Ramakrishna V, Fanger MW (2004) Mannose receptor-targeted vaccines. Expert Opin Biol Ther 4:1953–62
59. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG (2005) Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106:1278–85
60. He L-Z, Crocker A, Lee J, Mendoza-Ramirez J, Wang X-T, Vitale LA, O’Neill T, Petromilli C, Zhang H-F, Lopez J, Rohrer D, Keler T, Clynes R (2007) Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 178:6259–67
61. Bueter CL, Specht CA, Levitz SM (2013) Innate sensing of chitin and chitosan. PLoS Pathog 9:e1003080
62. Merzendorfer H (2011) The cellular basis of chitin synthesis in fungi and insects: common principles and differences. Eur J Cell Biol 90:759–69
63. Shrive AK, Moeller JB, Burns I, Paterson JM, Shaw AJ, Schlosser A, Sorensen GL, Greenhough TJ, Holmskov U (2014) Crystal structure of the tetrameric fibrinogen-like recognition domain of fibrinogen C domain containing 1 (FIBCD1) protein. J Biological Chem 289:2880–7
64. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA (2011) Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 73:479–501
65. Cash HL, Whitham CV, Behrendt CL, Hooper LV (2006) Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313:1126–30
66. Van Dyken SJ, Mohapatra A, Nussbaum JC, Molofsky AB, Thornton EE, Ziegler SF, McKenzie AN, Krummel MF, Liang HE, Locksley RM (2014) Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and gammadelta T cells. Immunity 40:414–24
67. Bueter CL, Lee CK, Wang JP, Ostroff GR, Specht CA, Levitz SM (2014) Spectrum and mechanisms of inflammasome activation by chitosan. J Immunol 192:5943–51
68. Balan V, Verestiuc L (2014) Strategies to improve chitosan hemocompatibility: a review. Eur Polym J 53:171–88
69. Dash M, Chiellini F, Ottenbrite RM, Chiellini E (2011) Chitosan—a versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci 36:981–1014
70. Zaman M, Chandrudu S, Toth I (2013) Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 3:100–9
71. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE (2010) Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 62:59–82
72. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51:81–96
73. Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJ, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, Osterhaus AD, Knight A, Oxford JS, Lapini G, Cox R, Lambkin-Williams R (2014) Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLoS One 9:e93761
74. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25:2085–94
75. Yao W, Peng Y, Du M, Luo J, Zong L (2013) Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity. Mol Pharm 10:2904–14
76. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A (2005) A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:597–606
77. Cassone A (2013) Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol 11:884–91
78. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss A, Vasilakos JP, Underhill DM (2011) Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. Nature 472:471–5
79. Rubin-Bejerano I, Abeijon C, Magnelli P, Grisafi P, Fink GR (2007) Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. Cell Host Microbe 2:55–67
80. Devi SJ (1996) Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841–4
81. Devi SJN, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, Bennett JE (1991) Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 59:3700–7
82. Fleuridor R, Lees A, Pirofski L (2001) A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol 166:1087–96
83. Chow SK, Casadevall A (2011) Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine 29:1891–8
84. Xin H, Cartmell J, Bailey JJ, Dziadek S, Bundle DR, Cutler JE (2012) Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One 7:e35106
85. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, Filler SG, Yeaman MR, Edwards JE Jr (2006) Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 194:256–60
86. Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt CS, Hennessey JP, Jr., French SW, Yeaman MR, Filler SG, Edwards JE, Jr. 2013. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine
87. Xue J, Chen X, Selby D, Hung CY, Yu JJ, Cole GT (2009) A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77:3196–208
88. Hurtgen BJ, Hung CY, Ostroff GR, Levitz SM, Cole GT (2012) Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis. Infect Immun 80:3960–74
89. Wuthrich M, Filutowicz HI, Klein BS (2000) Mutation of the WI-1 gene yields an attenuated Blastomyces dermatitidis strain that induces host resistance. J Clin Invest 106:1381–9
90. Wang H, LeBert V, Hung CY, Galles K, Saijo S, Lin X, Cole GT, Klein BS, Wuthrich M (2014) C-type lectin receptors differentially induce Th17 cells and vaccine immunity to the endemic mycosis of North America. J Immunol 192:1107–19